TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
Tyra Biosciences to Participate in Upcoming Investor Conferences
AquaBounty Technologies (NASDAQ:AQB) versus Tyra Biosciences (NASDAQ:TYRA) Head to Head Analysis
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Moderate Buy” from Brokerages
Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year High – Here’s Why
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
Tyra Biosciences Announces Participation at Upcoming Investor Events
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Tyra Biosciences Announces Participation at Upcoming Investor Events
Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
Tyra Biosciences to Participate at Upcoming Investor Conferences
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
Post-Election Insider Buying in These 6 Stocks Is Huge
Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
The Schall Law Firm Has Launched An Inquiry Into Tyra Biosciences Inc For Securities Law Violations And Investors Are Urged To Contribute
Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet